CAP7.1 for the Treatment of Advanced Stage, Therapy Refractory Lung and Biliary Tract Tumors
Status:
Terminated
Trial end date:
2017-04-10
Target enrollment:
Participant gender:
Summary
To assess the anti-tumor activity of CAP7.1 based on the observed objective response rate and
rate of disease stabilization, as defined by the below primary and secondary endpoints, in
patients with Non-Small Cell Lung Carcinoma (NSCLC), SCLC or biliary cancer who have
progressed despite one or more previous chemotherapy line.